Anya Biotech wins the Proefdiervrij Venture Challenge 2022
June 28, 2022Anya Biotech, representing Amsterdam UMC, has won the second edition of the Proefdiervrij Venture Challenge on the 22nd of April 2022. Their winning innovation is based on research from the Department of Medical Biology at the AMC. The team takes home €25.000, – in prize money to kick-start their venture based on human heart models to treat cardiac disease.
The Anya Biotech team, consisting of Harsha Devalla, Marc Roelofs and Sander van Leeuwe, participated in the second edition of the Proefdiervrij Venture Challenge. In this bootcamp program,
the participating teams have been guided in the process of translating their scientific breakthrough into a solid business case. This specific version of the Venture Challenge was organised by Proefdiervrij, a foundation idealizing a future without animal testing. The participating teams have brought forward innovations contributing to this cause. In the final, the teams presented in front of an expert jury consisting of Geert-Jan Mulder, Rianne Ellenbroek, Giel Hendriks, Jos Joore and Susan Janssen. The final presentations and subsequent award ceremony took place at Pathé Buitenhof in Den Haag.
The vision of Anya Biotech is to dramatically improve the quality of life of patients suffering from cardiac arrhythmias. They will develop therapies for cardiac arrhythmias such as Atrial Fibrillation and Pacemaker Dysfunction. The cardiac models of Anya Biotech are based on human stem cells, and they mimic the human heart more accurately than the models that are currently used for drug discovery (e.g. animal models). This significantly improves their chances of identifying effective drugs for cardiac arrhythmias, which are currently not effectively treatable.
From Amsterdam UMC also inSteps (location AMC) and Simplexable (location VUmc) participated in the Proefdiervrij Venture Challenge 2022.
Photo credits: Proefdiervrij
More news
Max Nieuwdorp’s innovative research on gut microbes: a path to combat fatty liver disease
Internist Max Nieuwdorp, of Amsterdam UMC, discovered a few years ago that the microorganisms in the intestines of many overweight people produce alcohol to an increased extent. Breaking down excessive alcohol leads to fatty liver disease, which in turn poses a risk of serious conditions such as diabetes and cardiovascular disease. Nieuwdorp has now received an ERC Advanced Grant of 2.5 million euros for a major study into the underlying causes of this excessive alcohol production.
News
Impact in education and beyond: VU researcher Laura Rupp secures Comenius Leadership Fellow grant
Laura Rupp has been awarded the Comenius Leadership Fellow grant for a three-year period. This grant of 500,000 Euros, will fund a project titled “Global English and International Dutch on the VU Campus”. Over the years, Rupp has successfully reached more than 100,000 people online worldwide, teaching how to understand diverse English accents and speak […]
News
Funding from KWF for palliative cancer patients in meaning-making at home
The diagnosis of incurable cancer profoundly disrupts patients’ lives, often causing existential crises and a sense of lost purpose. The KWF-funded project “In Search of Stories” (ISOS) aimed to support these patients by partnering them with spiritual counsellors and professional artists. This co-creation process proved highly beneficial. New funding from KWF Dutch Cancer Society supports […]
News